TY - JOUR
T1 - Potential neurological manifestations of COVID-19
T2 - a narrative review
AU - for the NEMA Research Group
AU - Pergolizzi, Joseph V.
AU - Raffa, Robert B.
AU - Varrassi, Giustino
AU - Magnusson, Peter
AU - LeQuang, Jo Ann
AU - Paladini, Antonella
AU - Taylor, Robert
AU - Wollmuth, Charles
AU - Breve, Frank
AU - Chopra, Maninder
AU - Nalamasu, Rohit
AU - Christo, Paul J.
N1 - Funding Information:
No funding was received for this article. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. No funding or sponsorship was received for this study or publication of this article.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Neurological manifestations are increasingly reported in a subset of COVID-19 patients. Previous infections related to coronaviruses, namely Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) also appeared to have neurological effects on some patients. The viruses associated with COVID-19 like that of SARS enters the body via the ACE-2 receptors in the central nervous system, which causes the body to balance an immune response against potential damage to nonrenewable cells. A few rare cases of neurological sequelae of SARS and MERS have been reported. A growing body of evidence is accumulating that COVID-19, particularly in severe cases, may have neurological consequences although respiratory symptoms nearly always develop prior to neurological ones. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. It is possible that in some COVID-19 patients, neurological symptoms are being overlooked or misinterpreted. To date, neurological manifestations of COVID-19 have been described largely within the disease trajectory and the long-term effects of such manifestations remain unknown.
AB - Neurological manifestations are increasingly reported in a subset of COVID-19 patients. Previous infections related to coronaviruses, namely Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) also appeared to have neurological effects on some patients. The viruses associated with COVID-19 like that of SARS enters the body via the ACE-2 receptors in the central nervous system, which causes the body to balance an immune response against potential damage to nonrenewable cells. A few rare cases of neurological sequelae of SARS and MERS have been reported. A growing body of evidence is accumulating that COVID-19, particularly in severe cases, may have neurological consequences although respiratory symptoms nearly always develop prior to neurological ones. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. It is possible that in some COVID-19 patients, neurological symptoms are being overlooked or misinterpreted. To date, neurological manifestations of COVID-19 have been described largely within the disease trajectory and the long-term effects of such manifestations remain unknown.
KW - COVID-19
KW - Coronavirus
KW - MERS
KW - SARS
KW - neurological symptoms
UR - http://www.scopus.com/inward/record.url?scp=85097025283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097025283&partnerID=8YFLogxK
U2 - 10.1080/00325481.2020.1837503
DO - 10.1080/00325481.2020.1837503
M3 - Review article
C2 - 33089707
AN - SCOPUS:85097025283
VL - 134
SP - 395
EP - 405
JO - Postgraduate Medicine
JF - Postgraduate Medicine
SN - 0032-5481
IS - 4
ER -